Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Entrada Therapeutics Inc. currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 2 distinct examiners and 3 distinct art units, suggesting a diverse range of technical subject matter within the portfolio. The presence of the identified art units relative to the 2 distinct examiners indicates that the portfolio is spread across different administrative groups at the office.
The busiest examiner for the company is VANHORN, ABIGAIL LOUISE, who is responsible for 3 pending office actions. This examiner handles the majority of the company's 4 pending office actions, representing a significant concentration of the portfolio's prosecution risk with a single individual. Practitioners should note that VANHORN, ABIGAIL LOUISE manages the bulk of the workload, while the remaining pending action is handled by the only other distinct examiner assigned to the portfolio.
The distribution of 3 distinct art units suggests that the company is pursuing protection for varied biological or pharmaceutical innovations. With the identified examiners involved, the company must navigate different examination styles, although the heavy concentration under a single examiner may allow for more consistent negotiation on the majority of the applications. The current pending office actions reflect the company's active efforts to expand its intellectual property holdings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 2 | 46.8% | +22.7% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289946 | COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING | VANHORN, ABIGAIL LOUISE | — |
| 18289944 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION | VANHORN, ABIGAIL LOUISE | — |
| 18553379 | CYCLIC CELL PENETRATING PEPTIDES | BRADLEY, CHRISTINA | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1635 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289946 | COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING | VANHORN, ABIGAIL LOUISE | 1636 | §103§112DP | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18289944 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION | VANHORN, ABIGAIL LOUISE | 1635 | §103§112DP | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18553379 | CYCLIC CELL PENETRATING PEPTIDES | BRADLEY, CHRISTINA | 1654 | §102§112DP | Non-Final OA | — | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEntrada Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 2 examiners.
Abigail Louise Vanhorn has the most, with 2 of Entrada Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
